Hipertiroidismo y sistema cardiovascular Bases fisiopatológicas y su ...

INSUFICIENCIA CARDIACA
Vol. 5, Nº 4, 2010
176 D Mantilla y col.
Hipertiroidismo y sistema cardiovascular
71. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as
a risk factor for atrial fibrillation. Am Heart J 2001;142:838-842.
72. Aras D, Maden O, Ozdemir O, Aras S, Topaloglu S, Yetkin E,
Demir AD, Soylu MO, Erdogan MF, Kisacik HL, Korkmaz
S. Simple electrocardiographic markers for the prediction of
paroxysmal atrial fibrillation in hyperthyroidism. Int J Cardiol
2005;99(1):59-64.
73. Taeko S, Saori K, Jaduk Y, et al. Hyperthyroidism and the management
of atrial fibrillation. Thyroid 2002;12:489-493.
74. Martin WH III, Spina RJ, Korte E. Effect of hyperthyroidism of
short duration on cardiac sensitivity to beta-adrenergic stimulation.
J Am Coll Cardiol 1992;19:185-191.
75. Forfar J. Atrial fibrillation and the pituitary-thyroid axis: a reevaluation.
Heart 1997;77:3-4.
76. Presti C, Hart R. Thyrotoxicosis, atrial fibrillation, and embolism,
revisited. Am Heart J 1989;273:1057-1061.
77. Loeliger E, Mattern M, Hemker H, et al. The biological disappearance
rate of prothrombin, factors VII, IX and X from plasma in
hypothyroidism, hyperthyroidism, and during fever. Thromb Diath
Haemorrh 1964;10:267-277.
78. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism
and risk of atrial fibrillation or flutter. Arch Intern Med
2004;164:1675-1678.
79. Falk R. Atrial fibrillation. N Engl J Med 2001;344:1067-1078.
80. Kim D, Smith T. Effects of thyroid hormone on sodium
pump sites, sodium content and contractile responses to cardiac
glycosides in cultured chick ventricular cells. J Clin Invest
1984;74:1481-1488.
Nakazawa K, Sakurai K, Hamada N, Momotani N, Ito K. Manage-
81.
ment of atrial fibrillation in the post-thyrotoxic state. Am J Med
1982;72:903-906.
Nakazawa H, Ishikawa N, Noh J, Sugimoto T, Yoshimoto M,
82.
Yashiro T, Ozaki O, Ito K. Efficacy of disopyramide in conversion
and prophylaxis of post-thyrotoxic atrial fibrillation. Eur J Clin
Pharmacol 1991;40:215-219.
Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger
83.
RW, Black IW, et al. Use of transesophageal echocardiography to
guide cardioversion in patients with atrial fibrillation. N Engl J
Med 2001;344:1411-1420.
84. Klein I. Thyroid hormone and the cardiovascular system. Am J
Med 1990;88:631-637.
85. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and heart.
Circulation 1993;87:1453-1441.
86. Bell GM, Sawers SA, Forfar JC, Doig A, Toft D. The effect of
minor increments in plasma thyroxine on heart rate and urinary
sodium excretion. Clin Endocrinol 1983;18:511-516.
Biondi B, Fazio S, Carella C, et al. Cardiac effects of long-term
87.
thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol
Metab 1993;77:334-338.
Polikar R, Feld GK, Dittrick FH, Smith J, Nicod P. Effect of thyroid
88.
replacement therapy on the frequency of benign atrial and ventricular
arrhythmias. J Am Coll Card 1989;14:999-1002.
Biondi B, Fazio S, Coltorti F, et al. Reentrant atrioventricular nodal
89.
tachycardia induced by levothyroxine. J Clin Endocrinol Metab
1998;83:2643-2645.
Ching GW, Franklyn JA, Stallard TJ, Daykin J, Sheppard M, Gam-
90.
mage MD. Cardiac hypertrophy as a result of long-term thyroxine
therapy and thyrotoxicosis. Heart 1996;75:363-368.
Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects
91.
in asymptomatic athyreotic patients chronically treated with
thyrotropin-suppressive doses ofL-thyroxine. J Clin Endocrinol
Metab 1997;82:2592-2595.
Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients
92.
on thyroid-stimulating-hormone suppressive therapy with levothyroxine:
beneficial effect of beta blockade. J Clin Endocrinol Metab
1995;80:2222-2226.
Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve
93.
and exercise capacity in patients receiving long-term thyrotropin
suppressive therapy with levothyroxine. J Clin Endocrinol Metab
1996;81:4224-4228.
Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical
94.
exercise capacity, and quality of life during long-term thyrotropinsuppressive
therapy with levothyroxine: effect of individual dose
tailoring. J Clin Endocrinol Metab 2000;85:159-164.
Biondi B, Fazio S, Carella C, et al. Control of adrenergic over
95.
activity by beta-blockade improves the quality of life in patients
receiving long-term suppressive therapy with levothyroxine. J Clin
Endocrinol Metab 1994;78:1028-1033.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli W.
96.
Prognostic implication of echocardiographically determined left
ventricular mass in the Framingham Heart Study. N Engl J Med
1990;322:1561-1566.
Boutin JM, Matte R, D’Amour P, et al. Characteristic of patients
97.
with normal T3 and T4 and low TSH response to TRH. Clin Endocrinol
1986;25:579-588.
Abe A, Yamamoto T, Isome M, et al. Thyroid hormone regulates
98.
expression of Shaker-related potassium channel mRNA in rat heart.
Biochem Biophys Res Commun 1998;245:226-230.
Williams LT, Lefkowitz RJ, Watanabe AM, Hathaway DR, Besch
99.
Jr HR. Thyroid hormone regulation of beta-adrenergic number. J
Biol Chem 1977;252:2787-2789.
Pachucki J, Burmeister L, Larsen PR. Thyroid hormone regu-
100.
lated hyperpolarization-activated cyclic nucleotide-gated channel
(HCN2) mRNA in the rat heart. Circ Res 1999;85:498-503.
Kannel WB, Kannel C, Paffenbarger Jr RS, Cupples LA. Heart
101.
rate and cardiovascular mortality: The Framingham Study. Am
Heart J 1987;113:1489-1494.
Utiger R. Subclinical hyperthyroidism -just a low serum thy-
102.
rotropin concentration, or something more? N Engl J Med
1994;77:332-333.
Benjamín E, Levy D, Vaziri S, et al. Independent risk factors for
103.
atrial fibrillation in a population-based cohort: the Framingham
Heart Study. JAMA 1994;2(71):840-844.
104. Auer J, Berent R, Weber T, Eber B. Hyperthyroidism. Lancet
2003;362:1584.
105. Haissaguerre M, Jais P, Shah D, Takahashi A, Hocini M, Quiniou
G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J. Spontaneous
initiation of atrial fibrillation by ectopic beats originating in
the pulmonary veins. N Engl J Med 1998;339:659-666.
Olshausen K, Bischoff S, Kahaly G, Mohr-Kahaly S, Erbel R,
106.
Beyer J, Meyer J. Cardiac arrhythmias and heart rate in hyperthyroidism.
Am J Cardiol 1989;63:930-933.
Osman F, Daykin J, Sheppard M, Franklyn J, Gammage M. Car-
107.
diac rhythm abnormalities in thyrotoxicosis. The explanation for
excess vascular mortality. J Endocrinol 2000;164:321.
108. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the
heart. Review. Circulation 1993;87:1435-1441.
109. Golf S, Lovstad R, Hansson V. Beta-adrenoceptor density and
relative number of beta-adrenoceptor subtypes in biopsies from
human right atrial, left ventricular and right ventricular myocardium.
Cardiovasc Res 1985;19:636-641.
Ojamaa K, Sabet A, Kenessey A, Shenoy R, Klein I. Regulation
110.
of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid
and chamber specific. Endocrinology 1999;140:3170-3176.
111. Summers V, Surtees S. Thyrotoxicosis and heart disease. Acta
Med Scand 1969;169:661-671.
112. Duan Y, Peng W, Wang X, Tang W, Liu X, Xu S, Mao X, Feng S,
Feng Y, Qin Y, et al. Community-based study of the association
of subclinical thyroid dysfunction with blood pressure. Endocr
2009;35(2):136-142.
113. Nordyke R, Gilbert F, Harada A. Graves’ disease: influence of age
on clinical findings. Arch Intern Med 1988;148:626-631.
114. Pereira N, Parisi A, Dec G, et al. Myocardial stunning in hyperthyroidism.
Clin Cardiol 2000;23:298-300.
115. Marti V, Ballester M, Obrador D, et al. Active myocardial damage
in hyperthyroidism. A concurrent mechanism of heart failure
reversed by treatment. Eur Heart J 1995;16:1014-1016.
Roti E, Montermini M, Roti S, et al. The effect of diltiazem, a
116.
calcium channel blocking drug, on cardiac rate and rhythm in
hyperthyroid patients. Arch Intern Med 1988;148:919-921.
Franklyn J, Maisonneuve P, Sheppard M, Betteridge J, Boyle P.
117.
Mortality after the treatment of hyperthyroidism with radioactive
iodine. N Engl J Med 1998;38:712-718.
118. Woeber K. Update on the management of hyperthyroidism and
hypothyroidism. Arch Intern Med 2000;160:1067-1070.
119. Hasnain M, Khandwala, et al. A case of congestive heart failure
due to reversible dilated cardiomyopathy caused by hyperthyroidism.
Southern Med J 2004;97;10:1001-1003.
Eiffel JA, Estes III NA, Waldo AL, Prystowsky EN, DiBianco
120.
R. A consensus report on antiarrhythmic drug use. Clin Cardiol
1994;17:103-116.
Newnham HH, Topliss DJ, Le Grand BA, Chosich N, Harper RW,
121.
Stockigt JR. Amiodarone-induced hyperthyroidism: assessment of
the predictive value of biochemical testing and response to com-